Sign In
Buy NERV
$4.68
-0.0700 (-1.47%)
At Close: Jun 03, 2026
Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis
01:26am, Wednesday, 31'st Dec 2025
UCB (OTCMKTS:UCBJY - Get Free Report) and Minerva Neurosciences (NASDAQ: NERV - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses b
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
08:30am, Wednesday, 19'th Nov 2025
Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will also serve as a consultant for roluperidone development.
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
07:30am, Wednesday, 05'th Nov 2025
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
08:00am, Tuesday, 21'st Oct 2025
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone's clinical
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
04:35pm, Thursday, 14'th Aug 2025
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
07:30am, Tuesday, 13'th May 2025
BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
07:00am, Tuesday, 25'th Feb 2025
BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
07:30am, Tuesday, 05'th Nov 2024
BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 06'th May 2024
Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
07:30am, Wednesday, 01'st May 2024
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv
US FDA declines to approve Minerva Neurosciences' schizophrenia drug
08:14am, Tuesday, 27'th Feb 2024
Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration has declined to approve its experimental drug for the treatment of negative symptoms in patients with schizophrenia.
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
07:00am, Thursday, 22'nd Feb 2024
BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
07:30am, Tuesday, 07'th Nov 2023
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences: There's Probably Time For One More Rally
04:05am, Wednesday, 23'rd Aug 2023
Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
07:30am, Tuesday, 01'st Aug 2023
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
